23.Issue 03 march 26 - INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

Volume : 13, Issue : 03, March – 2026

Title:

FORMULATION AND EVALUTION OF MESALMAINE SUSTAINED RELEASE TABLETS BY USING NATURAL POLYMER

Authors :

P. Adi Narayana Reddy, Dr. J . N. Suresh Kumar, B Sanjeevarao, K. Nirmal Jyothi, *K . Naga Pushyami, Sk. Neelima, V. Sahithi Sai

Abstract :

Evaluation of sustained release tablets of Mesalamine using natural polymers to enhance therapeutic efficacy and patient compliance in the treatment of inflammatory bowel disease. Sustained release systems are designed to deliver the drug at a controlled rate over an extended period, thereby reducing dosing frequency. Tablets were prepared by wet granulation using natural polymers such as xanthan gum and guar gum in varying concentrations as release-retarding agents.
Pre-compression parameters including angle of repose, bulk density, tapped density, Carr’s index, and Hausner’s ratio indicated satisfactory flow properties of the powder blends. Post-compression evaluation showed that the tablets met acceptable limits for weight variation, thickness, hardness, friability, and drug content. In-vitro dissolution studies were conducted for 24 hours using 0.1 N HCl for the first 2 hours followed by pH 6.8 phosphate buffer to simulate gastrointestinal conditions. Formulations with higher polymer concentrations exhibited prolonged and controlled drug release. The optimized formulation demonstrated a desirable sustained release profile. The formulation (f6) created has a highest drug release rate of all formulations tested.
Key words: Mesalamine, Sustained release, Natural polymers, xanthan gum, ftir

Cite This Article:

Please cite this article in press K . Naga Pushyami et al., Formulation And Evalution Of Mesalmaine Sustained Release Tablets By Using Natural Polymer., Indo Am. J. P. Sci, 2026; 13(03).

REFERENCES:

1. Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. 2017;389(10080):1756-70. Lancet.
2. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365(18):1713-25.
3. Ordás I, Eckmann L, Talamini M, et al. Ulcerative colitis. 2012;380(9853):1606-19. Lancet.
4. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12(4):205-17.
5. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427-34.
6. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of IBD. 2011;474(7351):307-17. [6] Nature.
7. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14(5):329 42. [7]
8. Ko JK, Auyeung KK. Inflammatory bowel disease: etiology, pathogenesis, and current therapy. Curr Pharm Des. 2014;20(7):1082-96.
9. Harbord M, Eliakim R, Bettenworth D, et al. European consensus on diagnosis and management of ulcerative colitis. J Crohns Colitis. 2017;11(6):649-70.
10. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of UC. J Crohns Colitis. 2012;6(10):991-1030.
11. Lachman L, Lieberman HA, Kanig JL. The Theory and Practice of Industrial Pharmacy. 3rd ed. Philadelphia: Lea & Febiger; 1986. p. 293–345.
12. Aulton ME, Taylor KMG. Aulton’s Pharmaceutics: The Design and Manufacture of Medicines. 5th ed. London: Elsevier; 2018. p. 457–482.
13. Banker GS, Anderson NR. Tablets. In: Lachman L, Lieberman HA, Kanig JL, editors. The Theory and Practice of Industrial Pharmacy. 3rd ed. Philadelphia: Lea & Febiger; 1986. p. 293– 345.
14. Ansel HC, Allen LV Jr, Popovich NG. Pharmaceutical Calculations. 15th ed. Philadelphia: Wolters Kluwer; 2021. p. 401–410.
15. Aulton ME, Taylor KMG. Aulton’s Pharmaceutics: The Design and Manufacture of Medicines. 5th ed. London: Elsevier; 2018. p. 101–110, 365–380.
16. Aulton ME, Taylor KMG. Aulton’s Pharmaceutics: The Design and Manufacture of Medicines. 5th ed. London: Elsevier; 2018. p. 101–110, 365–380.
17. Rowe RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. 7th ed. London: Pharmaceutical Press; 2012.
18. Martin A, Bustamante P, Chun AHC. Physical Pharmacy: Physical Chemical Principles in the Pharmaceutical Sciences. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2011.
19. Lachman L, Lieberman HA, Kanig JL. The Theory and Practice of Industrial Pharmacy. 3rd ed. Bombay: Varghese Publishing House; 1987. p. 128–185.
20. Allen LV Jr, Popovich NG, Ansel HC. Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems. 10th ed. Philadelphia: Wolters Kluwer; 2018.
21. Jain NK. Advances in Controlled and Novel Drug Delivery. New Delhi: CBS Publishers; 2001.p. 173–205.
22. Remington JP. Remington: The Science and Practice of Pharmacy. 24th ed. Philadelphia: Lippincott Williams & Wilkins; 2011.
23. Raghavan S, Hodge H. Xanthan gum. In: Rowe RC, Sheskey PJ, Quinn ME, editors. Handbook of Pharmaceutical Excipients. 7th ed. London: Pharmaceutical Press; 2012. p. 788–792.
24. PVP (Polyvinylpyrrolidone) monograph. In: Rowe RC, Sheskey PJ, Quinn ME, editors. Handbook of Pharmaceutical Excipients. 7th ed. London: Pharmaceutical Press; 2012. p. 610–612.
25. MCC (Microcrystalline Cellulose) monograph. In: Rowe RC, Sheskey PJ, Quinn ME, editors. Handbook of Pharmaceutical Excipients. London: Pharmaceutical Press; 2012. p. 424–426.
26. Talc monograph. In: Rowe RC, Sheskey PJ, Quinn ME, editors. Handbook of Pharmaceutical Excipients. London: Pharmaceutical Press; 2012. p. 682–684.
27. Magnesium stearate monograph. In: Rowe RC, Sheskey PJ, Quinn ME, editors. Handbook of Pharmaceutical Excipients. London: Pharmaceutical Press; 2012. p. 447–449.